Connect with us

Business

Fentanyl Overdoses See Dramatic Spike in U.S., According to Report

Published

on

Nearly 70,000 Americans died of fentanyl overdoses in 2021.

The number of deadly overdoses from fentanyl surged between 2016 and 2021, according to a disquieting new report from the U.S. Centers for Disease Control and Prevention.

The report, which was released on Wednesday, found that 69,943 died of a fentanyl-induced overdose in 2021 at a rate of 21.6. That is up considerably from 2016, when 18,499 died of an overdose from fentanyl at a rate of 5.7.

According to CNN, the Centers for Disease Control typically “reports overdose data by broader drug categories.”

“Fentanyl, for example, is grouped with other synthetic opioids like tramadol and nitazenes. But for Wednesday’s report, researchers took a closer look at the specific drugs that are included on death certificates for people who died of overdoses, highlighting demographic differences,” CNN reported.

Caleb Banta-Green, a research professor at the University of Washington School of Medicine’s Addictions, Drug & Alcohol Institute, told CNN that specifying the drug that caused the overdose is crucial for researchers.

“We need to know exactly what people are dying from so we know what services they need to stay alive,” said Banta-Green. 

The report found an increase in deadly overdose from several other drugs as well. 

“The age-adjusted rate of drug overdose deaths involving fentanyl more than tripled over the study period, from 5.7 per 100,000 standard population in 2016 to 21.6 in 2021, with a 55.0% increase from 2019 (11.2) to 2020 (17.4), and a 24.1% increase from 2020 to 2021 (21.6). The rate of drug overdose deaths involving methamphetamine more than quadrupled, from 2.1 in 2016 to 9.6 in 2021,” the CDC reported. The rate of drug overdose deaths involving cocaine more than doubled, from 3.5 in 2016 to 7.9 per 100,000 in 2021. The rate of drug overdose deaths involving heroin decreased by 40.8%, from 4.9 in 2016 to 2.9 in 2021, although this decrease was not statistically significant. The rate of drug overdose deaths involving oxycodone decreased 21.0%, from 1.9 in 2016 to 1.5 in 2021.” 

“In 2021, the age-adjusted rate of drug overdose deaths was highest for deaths involving fentanyl (21.6 per 100,000 standard population), followed by methamphetamine (9.6), cocaine (7.9), heroin (2.9), and oxycodone (1.5). Patterns were similar when stratified by sex,” the report continued.

The CDC said that it “analyzed literal text from the National Vital Statistics System mortality data for deaths occurring in the United States among U.S. residents.”

“From 2016 through 2021, age-adjusted drug overdose death rates involving fentanyl, methamphetamine, and cocaine increased, while drug overdose death rates involving oxycodone decreased,” the CDC reported. “In 2021, the age-adjusted death rates for males were higher than the rates for females for all drugs analyzed. Among those aged 25–64, the highest rate of drug overdose deaths involved fentanyl; although a similar pattern was observed among those aged 0–24 years and 65 and over, no significant differences were observed between the rates. Fentanyl was also the most frequent opioid or stimulant drug involved in drug overdose deaths for the race and Hispanic-origin groups analyzed.” 

As CNN said, “[p]harmaceutical fentanyl is a synthetic opioid intended to help patients, such as those with cancer, manage severe pain.” 

“It is 50 to 100 times more potent than morphine and typically prescribed in the form of skin patches or lozenges. But most recent cases of fentanyl-related harm, overdose and death in the United States are linked to illegally made fentanyl, according to the CDC,” CNN reported.

Source: https://hightimes.com/news/fentanyl-overdoses-see-dramatic-spike-in-u-s-according-to-report/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News